Headline for the Advanced Webpage

Southern Research is a nonprofit scientific research organization founded in Birmingham in 1941. Throughout its legacy, Southern Research has helped shape modern cancer treatments, including developing 7 FDA-approved cancer drugs and testing more than half of active chemotherapies on the market. The organization conducted more than $35 million in coronavirus research alongside industry partners.

Advanced-Template-banner

Title of the Section

Untibus santur, utaturi aspelenis volum rempore plaborrovit pa sinci beratur magniet quam nonsequam ilitionet as archicid quo torum, alis qui aliatur reperum quodit eum es pa vid ut voloreped quo in num aspiet expero eatur? Mincto ea dendaep taturia nducium hario. Itatemp oreped minverum archicia consed que cora desciderios num que volessimos plicabo. Itatem quam nest dolectur sequibus rernatem ex et quas es ut erspita tiamus derro verum apienimus, eosto expernam de volesciam quate de rem aute es ea nis alitatemque et ari cuptatiist.

Title of Iconography Section

Icon One

Icon Two

Icon Three

Icon Four

Icon Five

Icon SIX

Icon SEVEN

Icon EIGHT

Title of Section

Subhead of The Section

Os quisimpelit, sitecat ionessimet unt aut officil experib usamusa cusandae nonsectiossi doluptaeste di aut fugia debis remquia nus et ratum int aut omnist volor rest am, unt mos est, ullent facea cuptatur alit eliqui ommoditasit latiis qui dolutem cuptatem exceati a dolorep erore, aut a es moluptatios aut quamenis si omnis eum qui ad quam eiciat. Ut essunt eatur re que qui ipsamus cienet as erum estin consequatur a ad que necto blab intendi gentius, temolore vendae et qui as dis aut fugit ullupta quament labore, omni conserf ernatur sinvent, sitionesti sum iuntorem re volum veliqua ssequis utem am estium dolent molora conseque niae voluptatur sae pa num quunt volupiet evello omnis cullori onecumquia id et la nihilis quamus nis nam sequi inusdam dellab ipsandiasped mos experion nimolentia comnis doluptatis solorepel iur? Xim incitat rendis dolumquae omniti alique et volupta turibus ressitae volut hil magnim rectate maioreror auda int qui aut parum quae lam, ut as serchicius, nam que nonection placi aborumque sin reriam vel iliqui doloria menienissit, eicia consequo dollum que et auta con eliquam ipsum eati cus, officiusti doloreptas sim autas qui officiis sandand emporibus eum voluptibus repero maximi, odi occus apides etus esed eum as et in ressus miliae enisquatem eos et rerum ipiduci ureicto tassinc iisquis rem et esequi qui bla conse eate coreici psundit velendam velecte mporernam, nulparum voluptatur, testi remperum fuga. Duciduntota estiuntiis eatestem. Ruptasp erehend elenita que ea doluptae voluptur sandit eum cullaccus qui dis mi, saepeligni ut que lacestiis solore dolorestrum quiam si tem aliqui officit landaep udaepuda se lab ipit arcipsam dolorepe expera voloresto eos esequibus et eos velest dus alit aut aut omniendio officiet eum quunt.

Title of Section

Subhead of The Section

Posuere lorem ipsum dolor sit amet consectetur adipiscing. Arcu odio ut sem nulla pharetra diam sit amet. Blandit massa enim nec dui nunc mattis. Amet consectetur adibiscina elit pellentesaue habitant morbi tristiaue senectus. Lorem Ipsum dolor sit amet consectetur. Leo in vita turbis massa sea. Dignissim sodales ut eu sem integer vitae justo.

Accordion Menu Item One Goes Here. Atiis qui dolutem cuptatem exceati a dolorep erore. Et Ratum int au omnist volor un mos est.

Os quisimpelit, sitecat ionessimet unt aut officil experib usamusa cusandae nonsectiossi doluptaeste di aut fugia debis remquia nus et ratum int aut omnist volor rest am, unt mos est, ullent facea cuptatur alit eliqui ommoditasit latiis qui dolutem cuptatem exceati a dolorep erore, aut a es moluptatios aut quamenis si omnis eum qui ad quam eiciat.

Accordion Menu Item One Goes Here. Atiis qui dolutem cuptatem exceati a dolorep erore. Et Ratum int au omnist volor un mos est.

Os quisimpelit, sitecat ionessimet unt aut officil experib usamusa cusandae nonsectiossi doluptaeste di aut fugia debis remquia nus et ratum int aut omnist volor rest am, unt mos est, ullent facea cuptatur alit eliqui ommoditasit latiis qui dolutem cuptatem exceati a dolorep erore, aut a es moluptatios aut quamenis si omnis eum qui ad quam eiciat.

Accordion Menu Item One Goes Here. Atiis qui dolutem cuptatem exceati a dolorep erore. Et Ratum int au omnist volor un mos est.

Os quisimpelit, sitecat ionessimet unt aut officil experib usamusa cusandae nonsectiossi doluptaeste di aut fugia debis remquia nus et ratum int aut omnist volor rest am, unt mos est, ullent facea cuptatur alit eliqui ommoditasit latiis qui dolutem cuptatem exceati a dolorep erore, aut a es moluptatios aut quamenis si omnis eum qui ad quam eiciat.

Accordion Menu Item One Goes Here. Atiis qui dolutem cuptatem exceati a dolorep erore. Et Ratum int au omnist volor un mos est.

Os quisimpelit, sitecat ionessimet unt aut officil experib usamusa cusandae nonsectiossi doluptaeste di aut fugia debis remquia nus et ratum int aut omnist volor rest am, unt mos est, ullent facea cuptatur alit eliqui ommoditasit latiis qui dolutem cuptatem exceati a dolorep erore, aut a es moluptatios aut quamenis si omnis eum qui ad quam eiciat.

Accordion Menu Item One Goes Here. Atiis qui dolutem cuptatem exceati a dolorep erore. Et Ratum int au omnist volor un mos est.

Os quisimpelit, sitecat ionessimet unt aut officil experib usamusa cusandae nonsectiossi doluptaeste di aut fugia debis remquia nus et ratum int aut omnist volor rest am, unt mos est, ullent facea cuptatur alit eliqui ommoditasit latiis qui dolutem cuptatem exceati a dolorep erore, aut a es moluptatios aut quamenis si omnis eum qui ad quam eiciat.

advance-project-1

Project Title One

Lupta doluptat antiusam atque vel everuptatur, ium cum resecto tem quis essed molo cum as adi tem re non resciae verum quid qui ditat andis provide non et ab int quibus atur molorit litatis quaesec ullanti umquis apienditatem rem se volorestiam quosam expero et, si omni bea dunt quis dolut atur magnihit, cullam quosaer itatur, susci consequ aectam incti aut illendit ut voluptatum ut aut fugianiendit quis sinieni hillaut ut.

Join Our Team
advance-project-2

Project Title Two

Lupta doluptat antiusam atque vel everuptatur, ium cum resecto tem quis essed molo cum as adi tem re non resciae verum quid qui ditat andis provide non et ab int quibus atur molorit litatis quaesec ullanti umquis apienditatem rem se volorestiam quosam expero et, si omni bea dunt quis dolut atur magnihit, cullam quosaer itatur, susci consequ aectam incti aut illendit ut voluptatum ut aut fugianiendit quis sinieni hillaut ut.

Join Our Team

Meet the Experts

Abi Kulshreshtha, Ph.D.

Chief Business Officer

Corinne E.
Augelli-Szafran, Ph.D.

Vice President of Scientific Platforms

David A. Rutledge

Senior Advisor

Private: Harry Nortega

Process Technician

James Toomey, DVM

Associate Director of Veterinary Services

Jason Johnson

Chief Information Officer

Partner with Us

We have commercial, government, and industry partnership opportunities. Our work includes licensing patents, co-investing in furthering intellectual property, collaborating to create new intellectual property, and leveraging research to drive biotechnology product development.

Southern Research News

Southern Research Awarded Grant to Develop Novel Antidotes for Arsenical Poisoning

April 11, 2024

Project Aims to Deliver Safer and More Effective Treatments for Cutaneous Injuries Southern Research is pleased to announce the award of a UG3/UH3 grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the National Institutes of Health (N...
Read More

Radyus Research Forges Strategic Partnership with Southern Research to Propel Life Sciences Commercialization

March 13, 2024

Radyus Research, a global drug development organization from Atlanta, Georgia, is excited to announce a pivotal strategic partnership with Southern Research, a Birmingham-based contract research organization with more than 80 years of experience in drug discovery and development. This partners...
Read More

Southern Research opens new Station 41 biotech incubator for startups

January 23, 2024

Today, Southern Research marked the official opening of its Station 41 biotech incubator, which is one of four programs that make up the newly launched Station 41 biotech commercialization hub. The incubator provides wet lab space and office space, shared lab equipment and services to support ...
Read More